Sign up United Kingdom
Proactive Investors - Run By Investors For Investors

ValiRx chief says company is at an exciting phase as it updates on two key cancer candidates

Chief executive, Dr Satu Vainikka, said she looked forward to the “successful crystallisation of substantial value for patients and shareholders"
researcher filling a sample tray
The company has made significant clinical progress with both its drug candidates

ValiRx Plc (LON:VAL) said “commercial activity” around its lead cancer drug candidate has continued as it updated on both VAL401 and next in the queue, VAL201.

Chief executive, Dr Satu Vainikka, said she looked forward to the “successful crystallisation of substantial value for patients and shareholders".

“Since the pharmaceutical industry is increasingly looking for novel new therapies in the oncology arena, I believe we are in a new and very exciting phase,” she explained.

“VAL401 has demonstrated therapeutic efficacy, VAL201 is increasingly showing its therapeutic potential and our pre-clinical compounds and platform continue to progress along the value-chain and towards the clinic.”

Lung cancer treatment 

Preparations are currently being made to take the former which is being developed to tackle lung cancer, into final-stage clinical trials.

ValiRx said the principal investigators have now approved and signed the clinical study report and that the process of submission to and approval by the local ethics committees has commenced. 

“Detailed discussions are in progress in respect to a pivotal phase III trial,” the company said in its update. 

“Partners external to ValiRx and ValiSeek will have substantial input into the trial design, with first dosing anticipated next year.”

VAL201, meanwhile, has demonstrated “consistently high” safety and tolerability in hormone-sensitive and hormone-resistant prostate cancer patients taking part in the firm’s phase I/II trial.

Early inspection of data

Researchers have also made an inspection of the data derived from the original dosing regimen.

Highlighted was a dose-related impact on patients' physiology and chemistry.

Affected was androgen PSA (which regulates the expression of prostate cancer cells) as well as various cell and protein turnover factors important in the treatment of cancer. 

“These are in line with anticipated outcomes as far as cancer reduction is concerned,” the company added.

View full VAL profile View Profile

ValiRx Plc Timeline

Related Articles

test tubes
September 11 2018
Sierra Oncology is about to start the third trial of Sareum’s SRA737 Chk1 inhibitor, while internally, Sareum is making “good progress” with its TYK2 inhibitor programme
surgeons working
September 03 2018
Chief executive Steve Couldwell also told investors the regenerative medicines specialist had identified a number of potential new commercial opportunities it was “actively pursuing”
July 25 2018
Under former chief executive Peter George and his successor Shaun Chilton, Clinigen has been transformed via a series of well-judged, quickly integrated and cash generative acquisitions

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use